NOT FOR DISTRIBUTION
Header cover image

Market Cap

€1.4b

Last Updated

2021/05/10 02:29 UTC

Data Sources

Company Financials +

Executive Summary

Fagron NV, a pharmaceutical compounding company, provides personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients. More Details


Snowflake Analysis

Good value with reasonable growth potential.


Similar Companies

Share Price & News

How has Fagron's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: Insufficient data to determine FAGRB's volatility over the past 3 months.

Volatility Over Time: Insufficient data to determine FAGRB's volatility change over the past year.


Market Performance


7 Day Return

0%

FAGRB

0.7%

GB Healthcare

2.1%

GB Market


1 Year Return

-3.7%

FAGRB

52.5%

GB Healthcare

26.3%

GB Market

Return vs Industry: FAGRB underperformed the UK Healthcare industry which returned 52.5% over the past year.

Return vs Market: FAGRB underperformed the UK Market which returned 26.3% over the past year.


Shareholder returns

FAGRBIndustryMarket
7 Day0%0.7%2.1%
30 Day-2.9%7.4%3.5%
90 Day-8.7%12.0%8.8%
1 Year-3.5%-3.7%54.6%52.5%31.9%26.3%
3 Year31.2%29.5%-14.4%-18.7%12.9%-0.1%
5 Year184.1%160.7%-15.6%-21.6%51.5%22.8%

Long-Term Price Volatility Vs. Market

How volatile is Fagron's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Fagron undervalued compared to its fair value and its price relative to the market?

48.9%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: FAGRB (€19.04) is trading below our estimate of fair value (€37.28)

Significantly Below Fair Value: FAGRB is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: FAGRB is good value based on its PE Ratio (22.8x) compared to the GB Healthcare industry average (32.6x).

PE vs Market: FAGRB is good value based on its PE Ratio (22.8x) compared to the UK market (26.4x).


Price to Earnings Growth Ratio

PEG Ratio: FAGRB is poor value based on its PEG Ratio (1.3x)


Price to Book Ratio

PB vs Industry: FAGRB is overvalued based on its PB Ratio (5.4x) compared to the GB Healthcare industry average (2.1x).


Future Growth

How is Fagron forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

17.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: FAGRB's forecast earnings growth (17.6% per year) is above the savings rate (0.9%).

Earnings vs Market: FAGRB's earnings (17.6% per year) are forecast to grow faster than the UK market (17.5% per year).

High Growth Earnings: FAGRB's earnings are forecast to grow, but not significantly.

Revenue vs Market: FAGRB's revenue (8.3% per year) is forecast to grow faster than the UK market (5.3% per year).

High Growth Revenue: FAGRB's revenue (8.3% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: FAGRB's Return on Equity is forecast to be high in 3 years time (22.4%)


Past Performance

How has Fagron performed over the past 5 years?

60.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: FAGRB has high quality earnings.

Growing Profit Margin: FAGRB's current net profit margins (10.7%) are higher than last year (10.3%).


Past Earnings Growth Analysis

Earnings Trend: FAGRB has become profitable over the past 5 years, growing earnings by 60.4% per year.

Accelerating Growth: FAGRB's earnings growth over the past year (7.9%) is below its 5-year average (60.4% per year).

Earnings vs Industry: FAGRB earnings growth over the past year (7.9%) underperformed the Healthcare industry 15.3%.


Return on Equity

High ROE: Whilst FAGRB's Return on Equity (23.29%) is high, this metric is skewed due to their high level of debt.


Financial Health

How is Fagron's financial position?


Financial Position Analysis

Short Term Liabilities: FAGRB's short term assets (€221.9M) exceed its short term liabilities (€200.3M).

Long Term Liabilities: FAGRB's short term assets (€221.9M) do not cover its long term liabilities (€294.8M).


Debt to Equity History and Analysis

Debt Level: FAGRB's debt to equity ratio (124.8%) is considered high.

Reducing Debt: FAGRB had negative shareholder equity 5 years ago, but is now positive and has therefore improved.

Debt Coverage: FAGRB's debt is well covered by operating cash flow (28.9%).

Interest Coverage: FAGRB's interest payments on its debt are well covered by EBIT (8.8x coverage).


Balance Sheet


Dividend

What is Fagron current dividend yield, its reliability and sustainability?

0.95%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: FAGRB's dividend (0.96%) isn’t notable compared to the bottom 25% of dividend payers in the UK market (1.35%).

High Dividend: FAGRB's dividend (0.96%) is low compared to the top 25% of dividend payers in the UK market (4.03%).


Stability and Growth of Payments

Stable Dividend: FAGRB's dividend payments have been volatile in the past 10 years.

Growing Dividend: FAGRB's dividend payments have fallen over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its low payout ratio (21.8%), FAGRB's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: FAGRB's dividends in 3 years are forecast to be well covered by earnings (19.4% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.3yrs

Average management tenure


CEO

Rafael Padilla (42 yo)

3.5yrs

Tenure

€768,000

Compensation

Mr. Rafael Padilla has been Chief Executive Officer at Fagron NV since November 27, 2017 and served as its Area General Manager of South America and Southern Europe since October 25, 2016. Mr. Padilla serv...


CEO Compensation Analysis

Compensation vs Market: Rafael's total compensation ($USD933.40K) is below average for companies of similar size in the UK market ($USD1.36M).

Compensation vs Earnings: Rafael's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: FAGRB's management team is considered experienced (3.3 years average tenure).


Board Members

Experienced Board: FAGRB's board of directors are considered experienced (4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Fagron NV's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Fagron NV
  • Ticker: FAGRB
  • Exchange: BATS-CHIXE
  • Founded: 1990
  • Industry: Health Care Distributors
  • Sector: Healthcare
  • Market Cap: €1.364b
  • Shares outstanding: 72.37m
  • Website: https://www.fagron.com

Number of Employees


Location

  • Fagron NV
  • Venecoweg 20A
  • Nazareth
  • East Flanders
  • 9810
  • Belgium

Listings


Biography

Fagron NV, a pharmaceutical compounding company, provides personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients. It prepares personalized ready-to-use medication in its sterile a...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/05/10 02:29
End of Day Share Price2021/04/30 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.